Siemens Healthineers Faces Twin Squeeze from Berlin Austerity and Diagnostics Weakness

Siemens Healthineers shares languish near 52-week low despite European roadshow, after guidance cut and German healthcare savings package. Analysts see 45% upside but market remains skeptical.

Siemens Healthineers is trying to reassure investors on a European roadshow, but the medical technology group’s stock remains pinned near its 52-week low as political and operational pressures mount. Shares in the DAX-listed company edged up 1.31 percent to €34.11 on Thursday, but that small bounce does little to mask the year-to-date decline of 23.24 percent. The current price sits more than 20 percent below its 200-day moving average of €42.08 and a long way from the 52-week high of roughly €50.

The management team, led by a newly restructured executive level, has been pitching to institutional investors in Paris and Luxembourg after cutting the full-year guidance in May. Revenue growth for fiscal 2026 is now seen at 4.5 to 5.0 percent, down from an earlier forecast of up to 6 percent, while adjusted earnings per share are expected to land between €2.20 and €2.30. Analysts polled by the company have a consensus target of €49.06, implying upside of more than 45 percent, but the market clearly doubts those projections — the chasm between price target and current price is unusually wide.

Adding to the pressure is a regulatory crackdown in Berlin. Health Minister Nina Warken is pushing through a reform of the nursing care insurance system aimed at closing multibillion-euro deficits without raising contributions, while statutory health insurers defend a hard savings package. The impact is already visible: Eli Lilly has halved planned investments in Alzey, and Boehringer Ingelheim is pulling hundreds of millions of euros out of Germany. For Siemens Healthineers, which supplies equipment and services to hospitals, any squeeze on the healthcare system translates directly into weaker demand. The Bundesrat is set to debate the controversial savings package next week.

On the operational side, the picture is mixed. Imaging and Precision Therapy continue to perform solidly, but the laboratory diagnostics business is struggling with structural headwinds, notably reforms in China’s healthcare market that are slowing growth. To signal internal confidence, the company launched a share buyback programme in early June with a volume of up to €230 million, covering as many as 14 million shares through January 2027. However, the repurchased shares are earmarked primarily for employee compensation schemes rather than cancellation, limiting the direct benefit to existing holders.

Investors are now waiting for the third-quarter results, expected in July, to see whether the guidance cut was a one-off adjustment or the start of a deeper trend. Meanwhile, analysts remain cautiously constructive on the stock despite the weak price action: Barclays reiterated its “Overweight” rating in May, Jefferies and JP Morgan also recommend buying, while Deutsche Bank holds a more conservative “Hold”. The roadshow will move on to healthcare conferences in the US and UK after the European leg, as management tries to close the credibility gap between its own forecasts and the market’s scepticism.